Tekla Life Sciences Investors
HQL · NYSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.09 | -0.00 | 0.05 |
| FCF Yield | -0.29% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -7.76 | 0.00 | 3.64 | -29.18 |
| Quality | ||||
| ROIC | 0.00% | -0.27% | -0.15% | -2.84% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 91.24% |
| Cash Conversion Ratio | 0.02 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -9.33% | -5.11% | 28.56% | 142.80% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 31.59 | 10.86 | 4.92 | 15.36 |